ResMed Statistics

Total Valuation

ResMed has a market cap or net worth of AUD 56.38 billion. The enterprise value is 55.57 billion.

Market Cap	56.38B
Enterprise Value	55.57B

Important Dates

The next estimated earnings date is Thursday, January 22, 2026.

Earnings Date	Jan 22, 2026
Ex-Dividend Date	Nov 12, 2025

Share Statistics

Current Share Class	n/a
Shares Outstanding	n/a
Shares Change (YoY)	-0.28%
Shares Change (QoQ)	-0.09%
Owned by Insiders (%)	0.53%
Owned by Institutions (%)	69.03%
Float	144.84M

Valuation Ratios

The trailing PE ratio is 25.94 and the forward PE ratio is 22.94.

PE Ratio	25.94
Forward PE	22.94
PS Ratio	7.09
PB Ratio	6.09
P/TBV Ratio	14.18
P/FCF Ratio	21.09
P/OCF Ratio	19.80
PEG Ratio	n/a

Financial Ratio History

Enterprise Valuation

The stock's EV/EBITDA ratio is 18.60, with an EV/FCF ratio of 20.79.

EV / Earnings	25.56
EV / Sales	7.01
EV / EBITDA	18.60
EV / EBIT	20.86
EV / FCF	20.79

Financial Position

The company has a current ratio of 2.89, with a Debt / Equity ratio of 0.14.

Current Ratio	2.89
Quick Ratio	1.87
Debt / Equity	0.14
Debt / EBITDA	0.43
Debt / FCF	0.48
Interest Coverage	n/a

Financial Efficiency

Return on equity (ROE) is 25.41% and return on invested capital (ROIC) is 16.93%.

Return on Equity (ROE)	25.41%
Return on Assets (ROA)	14.18%
Return on Invested Capital (ROIC)	16.93%
Return on Capital Employed (ROCE)	24.99%
Revenue Per Employee	749,874
Profits Per Employee	205,091
Employee Count	10,600
Asset Turnover	0.68
Inventory Turnover	2.03

Taxes

In the past 12 months, ResMed has paid 458.04 million in taxes.

Income Tax	458.04M
Effective Tax Rate	17.40%

Stock Price Statistics

The stock price has increased by +1.86% in the last 52 weeks. The beta is 0.87, so ResMed's price volatility has been lower than the market average.

Beta (5Y)	0.87
52-Week Price Change	+1.86%
50-Day Moving Average	39.70
200-Day Moving Average	39.10
Relative Strength Index (RSI)	51.06
Average Volume (20 Days)	1,174,081

Short Selling Information

Short Interest	n/a
Short Previous Month	n/a
Short % of Shares Out	n/a
Short % of Float	n/a
Short Ratio (days to cover)	10.34

Income Statement

In the last 12 months, ResMed had revenue of AUD 7.95 billion and earned 2.17 billion in profits. Earnings per share was 14.77.

Revenue	7.95B
Gross Profit	4.82B
Operating Income	2.66B
Pretax Income	2.63B
Net Income	2.17B
EBITDA	2.93B
EBIT	2.66B
Earnings Per Share (EPS)	14.77

Full Income Statement

Balance Sheet

The company has 2.09 billion in cash and 1.28 billion in debt, giving a net cash position of 812.64 million.

Cash & Cash Equivalents	2.09B
Total Debt	1.28B
Net Cash	812.64M
Net Cash Per Share	n/a
Equity (Book Value)	9.25B
Book Value Per Share	63.41
Working Capital	3.58B

Full Balance Sheet

Cash Flow

In the last 12 months, operating cash flow was 2.85 billion and capital expenditures -173.85 million, giving a free cash flow of 2.67 billion.

Operating Cash Flow	2.85B
Capital Expenditures	-173.85M
Free Cash Flow	2.67B
FCF Per Share	n/a

Full Cash Flow Statement

Margins

Gross margin is 60.69%, with operating and profit margins of 33.52% and 27.35%.

Gross Margin	60.69%
Operating Margin	33.52%
Pretax Margin	33.11%
Profit Margin	27.35%
EBITDA Margin	36.87%
EBIT Margin	33.52%
FCF Margin	33.64%

Dividends & Yields

This stock pays an annual dividend of 0.52, which amounts to a dividend yield of 1.35%.

Dividend Per Share	0.52
Dividend Yield	1.35%
Dividend Growth (YoY)	14.63%
Years of Dividend Growth	n/a
Payout Ratio	22.31%
Buyback Yield	0.28%
Shareholder Yield	1.63%
Earnings Yield	3.86%
FCF Yield	4.74%

Dividend Details

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value
Lynch Upside
Graham Number
Graham Upside

Stock Splits

The last stock split was on August 12, 2010. It was a forward split with a ratio of 2.

Last Split Date	Aug 12, 2010
Split Type	Forward
Split Ratio	2

Scores

ResMed has an Altman Z-Score of 12.67 and a Piotroski F-Score of 6.

Altman Z-Score	12.67
Piotroski F-Score	6